ID   HPB-MLT
AC   CVCL_7959
SY   FCCH1019
DR   BioSample; SAMN03151780
DR   cancercelllines; CVCL_7959
DR   Cosmic; 721703
DR   Cosmic; 801733
DR   Cosmic; 998731
DR   RCB; RCB1937
DR   TKG; TKG 0361
DR   Wikidata; Q54890237
RX   PubMed=203546;
RX   PubMed=1370437;
RX   PubMed=1373528;
RX   PubMed=2140233;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3874327;
RX   PubMed=6198871;
RX   PubMed=6749281;
RX   PubMed=8099376;
RX   PubMed=10071127;
RX   PubMed=10849313;
RX   PubMed=12592342;
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a HPB-ALL derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from a 62 year old female patient with a T-cell lymphoid malignancy.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00212.
CC   Population: Japanese.
CC   Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 29824; MYL11; Name(s)=CBFB-MYL11, CBFB-MYLPF (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1574Pro (c.4721T>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asp2442fs*39 (c.7326_7326insGGGCCGTGGACG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys124Ter (c.372C>A); ClinVar=VCV000458537; Zygosity=Homozygous (from parent cell line).
CC   Misspelling: MPB-MLT; PubMed=10071127.
CC   Discontinued: RCB; RCB1937; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8,10
ST   D16S539: 9,11
ST   D5S818: 11
ST   D7S820: 11
ST   TH01: 7,9
ST   TPOX: 8,12
ST   vWA: 18,20
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1820 ! HPB-ALL
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   PubMed=203546; DOI=10.1002/ijc.2910210207;
RA   Morikawa S., Tatsumi E., Baba M., Harada T., Yasuhira K.;
RT   "Two E-rosette-forming lymphoid cell lines.";
RL   Int. J. Cancer 21:166-170(1978).
//
RX   PubMed=1370437; DOI=10.1002/ijc.2910500223;
RA   Treichel R.S., Olken S.;
RT   "The relationship between multi-drug resistance and resistance to
RT   natural-killer-cell and lymphokine-activated killer-cell lysis in
RT   human leukemic cell lines.";
RL   Int. J. Cancer 50:305-310(1992).
//
RX   PubMed=1373528;
RA   Duan D.-S., Smith W., Sadee W., Cowan M.J.;
RT   "Characterization of three T-lymphoid cell lines with distinct
RT   sensitivities to deoxyadenosine plus deoxycoformycin.";
RL   Thymus 19:1-11(1992).
//
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=6198871; DOI=10.18926/AMO/32400;
RA   Oda T., Watanabe S., Nakamura T.;
RT   "Type C virus particles produced in human T-cell lines derived from
RT   acute lymphoblastic leukemia and a leukemic T-lymphoid malignancy.";
RL   Acta Med. Okayama 37:529-533(1983).
//
RX   PubMed=6749281; DOI=10.1002/1097-0142(19821101)50:9<1775::AID-CNCR2820500922>3.0.CO;2-T;
RA   Kanazawa S., Morikawa S., Harada T., Yasuhira K., Matsubara Y.,
RA   Ikeda S., Soeda S., Fujimura M.;
RT   "Carcinoembryonic antigen producing cultured cell lines enable
RT   detection of autoantibodies in sera from patients with
RT   gastrointestinal cancer.";
RL   Cancer 50:1775-1782(1982).
//
RX   PubMed=8099376; DOI=10.1016/0145-2126(93)90124-4;
RA   Treichel R.S.;
RT   "Autologous bone marrow transplantation for leukemia: monoclonal
RT   antibody-mediated purging of multidrug-resistant leukemia.";
RL   Leuk. Res. 17:491-499(1993).
//
RX   PubMed=10071127; DOI=10.1016/S0145-2126(98)00146-5;
RA   Kawamura M., Ohnishi H., Guo S.X., Sheng X.-M., Minegishi M.,
RA   Hanada R., Horibe K., Hongo T., Kaneko Y., Bessho F., Yanagisawa M.,
RA   Sekiya T., Hayashi Y.;
RT   "Alterations of the p53, p21, p16, p15 and RAS genes in childhood
RT   T-cell acute lymphoblastic leukemia.";
RL   Leuk. Res. 23:115-126(1999).
//
RX   PubMed=10849313; DOI=10.1046/j.1440-1827.2000.01040.x;
RA   Nagasaki M., Morikawa S., Torii I., Zhang J., Morikawa K.;
RT   "A human B-lineage dendritic cell line, HBM-Noda and its potential
RT   role in human T-cell leukemia/lymphoma virus type I infection.";
RL   Pathol. Int. 50:280-290(2000).
//
RX   PubMed=12592342; DOI=10.1038/sj.leu.2402799;
RA   Drexler H.G., Dirks W.G., Matsuo Y., MacLeod R.A.F.;
RT   "False leukemia-lymphoma cell lines: an update on over 500 cell
RT   lines.";
RL   Leukemia 17:416-426(2003).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//